- Stephen Doyle has more than 24
years of experience in the global pharmaceutical industry,
including leadership positions with companies such as Sanofi
Aventis and Boehringer Ingelheim. He was most recently Chief
Business Officer at Aslan Pharmaceuticals.
- Mr Doyle brings extensive knowledge in leading negotiations for
pharmaceutical assets across a range of deal types, licensing deals
across multiple geographies and commercialisation strategies.
BRISBANE, Australia, Aug. 5, 2024
/PRNewswire/ -- QBiotics Group Limited (QBiotics) is pleased
to announce the appointment of Stephen
Doyle, as Chief Executive Officer effective 2 September 2024.
Mr Doyle is a global pharmaceutical executive with more than 24
years' experience gained across a range of specialties within the
medical and pharmaceutical sectors in both developed and emerging
markets.
A pharmacist by training, Stephen has held a number of senior
leadership roles at top pharmaceutical companies globally during
the past two decades. Starting his career at Janssen Cilag and
Novartis in Sydney, he was
appointed to lead medical affairs of the Oncology Business Unit at
Sanofi Aventis (later Sanofi). Over the next ten years, the
expansion of Stephen's remit within Sanofi saw him relocating to
Europe and Asia to oversee scientific communications,
then commercial operations of the oncology arm in each market. As
Vice President of Oncology, Haematology and Transplantation
Business Unit in Shanghai, Stephen
launched new indications for Sanofi's drug assets across
China, while controlling a P&L
accountability of €140M to build a high-performing team culture
that translated into double-digit brand growth.
At Boehringer Ingelheim, Stephen led the Specialty Care Business
Unit (Oncology, Biosimilars and Rare Diseases) and later the
Diabetes Business Unit in Shanghai, managing multiple aspects of the
operation including new drug launches, launch readiness,
partnership and deal negotiation, team and brand management and
evaluation. In 2018 Stephen joined Aslan Pharmaceuticals as the
General Manager in China, moving
to Singapore as Chief Business
Officer to support the growth of Aslan's immunology and dermatology
assets in late-stage development.
He holds a Master of Science in Clinical Pharmacy from the
University of Derby and a Bachelor of Science (Honours) in Pharmacy
from the Robert Gordon University.
QBiotics' Executive Chair, Dr Susan
Foden commented, "On behalf of the Board, I am delighted
to welcome Stephen as QBiotics' CEO. The Board conducted an
extensive selection process and is confident that Stephen's
strategic track-record, which has led to several successful
licensing and commercialisation outcomes, will make him a strong
addition to the team as we continue to focus on our ambitious
development plans."
Commenting on his appointment, Stephen said: "It is a
privilege to be appointed CEO of QBiotics, a Company with a unique
and impressive history. QBiotics' focus aligns well the expertise I
have built across the past 20 years, dedicated to the
discovery and development of new drugs, bringing them to market,
and diversifying treatment options for patients. I am
committed to working with the Board and team to continue to
position the business to drive long-term value for the Company and
its shareholders."
We acknowledge the assistance and support of Coulter Partners in
facilitating the appointment.
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company
that specialises in the discovery and development of novel cell
signalling small molecules. QBiotics applies phenotypic screening
to generate breakthrough innovation in the discovery of first in
class solutions to challenging medical conditions. Our current
clinical focus is on novel treatments for cancer and debilitating
chronic wounds.
QBiotics' lead oncology drug, tigilanol tiglate, is a small
molecule targeting a range of solid tumours and is currently in
human clinical Phase II development. A veterinary formulation of
tigilanol tiglate is registered and marketed as an oncology
pharmaceutical, under the trade name STELFONTA®, in the
USA, Europe, the UK and Australia.
QBiotics' lead wound healing drug candidate, EBC 1013 is a small
molecule targeting a range of wounds including chronic and acute
wounds and burns. A first-in-human Phase I clinical development in
patients with venous leg ulcers is open for recruitment.
https://qbiotics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/qbiotics-welcomes-stephen-doyle-as-chief-executive-officer-302214171.html
SOURCE QBiotics Group Limited